Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ: PCRX )

25.96 +0.48 (+1.88%)
Streaming Delayed Price Updated: 11:15 AM EST, Feb 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 160,507
Open 25.34
Bid (Size) 25.94 (1)
Ask (Size) 25.98 (3)
Prev. Close 25.48
Today's Range 25.31 - 26.10
52wk Range 11.16 - 31.67
Shares Outstanding 44,454,792
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Pacira to Report 2024 Financial Results on Thursday February 27, 2025
From Pacira BioSciences
Via GlobeNewswire

Performance

YTD
+41.63%
+41.63%
1 Month
+1.17%
+1.17%
3 Month
+56.01%
+56.01%
6 Month
+74.23%
+74.23%
1 Year
-13.03%
-13.03%

More News

Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
From Faruqi & Faruqi LLP
Via GlobeNewswire
What 8 Analyst Ratings Have To Say About Pacira BioSciences
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March
From Pacira BioSciences
Via GlobeNewswire
For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals.
Via Chartmill
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate
Via Benzinga
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
From Faruqi & Faruqi LLP
Via GlobeNewswire
Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued.
Via Chartmill
PCRX Stockholders Should Contact Shareholder Rights Firm Robbins for Information About the Class Action Against Pacira BioSciences, Inc.
From Robbins LLP
Via GlobeNewswire
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
Pacira Announces Updates to Board of Directors
From Pacira BioSciences
Via GlobeNewswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
From Faruqi & Faruqi LLP
Via GlobeNewswire
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.